ACUMEN PHARMACEUTICALS INC (ABOS)
US00509G2093 - Common Stock
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage...
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured...
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first...
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acumen Pharmaceuticals (NASDAQ:ABOS) just reported results for the fourth quart...
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of...
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage...
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company...
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD - Poster...
Bullish Two Hundred Day Moving Average Cross - ABOS
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase...
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company...
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding.
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population.
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Acumen Pharmaceuticals to present at the JPMorgan Healthcare Conference....
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan...
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024,...
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
3 Promising Biotech Stocks Flying Under the Radar
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage...